CytoDyn Inc.

CYDY ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2018 FY2017 FY2016 FY2015 FY2014 FY2013 FY2012 FY2011
Operating Activities
Net Income $-50.1M $-25.8M $-25.7M $-25.1M $-12.4M $-9.6M $-7.5M $-3.7M
Depreciation & Amortization $356.1K $366.4K $361.6K $360.6K $352.4K $222.7K $2.0K $2.9K
Depreciation — — — — — — — —
Amortization — — — — $350.0K $219.0K — —
Stock-Based Compensation $1.3M $1.2M $2.4M $631.3K $928.4K $3.6M $2.9M $1.2M
Net Cash from Operating Activities $-29.9M $-26.7M $-24.8M $-12.0M $-7.4M $-3.4M $-4.4M $-1.8M
Investing Activities
Capital Expenditures $0 $11.1K $11.9K $18.6K $19.2K $3.1K — $4.7K
Business Acquisitions — — — — — — — —
Net Cash from Investing Activities $0 $-11.1K $-11.9K — $-19.2K $-3.5M — $-4.7K
Financing Activities
Dividends Paid — — — — — — — —
Stock Repurchases — — — — — — — —
Net Cash from Financing Activities $29.4M $18.9M $33.4M — — $7.2M $3.6M $2.2M
Net Change in Cash $-544.1K $-7.9M $8.6M $-3.8M $4.3M $318.7K $-752.8K $337.3K
Free Cash Flow $-29.9M $-26.7M $-24.8M $-12.0M $-7.4M $-3.4M — $-1.8M
← Newer Page 2 of 2 Older →